Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene therapy
Biotech
Ultragenyx shrinks workforce and axes assets to halve R&D spend
Ultragenyx is laying off 20% of its staff and axing drug development programs to cut its annual R&D budget to half of the amount it spent in 2025.
Nick Paul Taylor
Nov 4, 2026 5:19am
FDA grants uniQure priority review of its Huntington’s drug
Nov 2, 2026 4:12pm
Estuary emerges with $103M for kidney disease gene therapies
Oct 16, 2026 6:30am
Atsena's gene therapy readout illuminates eye disease efficacy
Oct 7, 2026 9:09am
uniQure stock crashes as Huntington’s gene therapy data weaken
Sep 29, 2026 9:28am
Lilly drops another gene therapy trial from $1B Prevail buyout
Aug 5, 2026 9:10am
